GeneNews signs first U.S. regional marketing partner for ColonSentry

GeneNews (TSX:GEN) has licensed its ColonSentry blood test for colorectal cancer to Enzo Clinical Labs, with exclusive rights to market the test in New York and New Jersey. In a statement, GeneNews said Enzo (NYSE:ENZ) will validate and seek approval of the ColonSentry test under New York, New Jersey and Clinical Laboratory Improvement Amendments (CLIA) [...]

Microbix signs distributor for Kinlytic

Microbix Biosystems (TSX:MBX) has landed Riso Pharma to distribute its Kinlytic drug in the Middle East, with Riso guaranteeing to purchase no less than 50,000 vials of the treatment for pulmonary embolism over the next three years. Sales are expected to begin in mid-2010.  “While final pricing for our therapy has not yet been established, [...]

Stellar plugging bladder wall around the world

In 2003, Lana Tenney began chemotherapy following her breast cancer surgery.  And as stressful as that was, things quickly worsened.  She developed a side-effect from chemotherapy called cystitis, a painful bladder condition that oncologists see in 10%-to-15% of cancer patients, who feel an urge to urinate 20-to-30 times a day, whether they can or can’t. [...]

Cannasat names Giovinazzo as CEO

Cannasat Therapeutics (TSX-V:CTH) has named Anthony Giovinazzo as president and CEO, succeeding co-founder David Hill, who will remain vice chairman and an advisor to Mr. Giovinazzo. “We are delighted that Anthony has agreed to join Cannasat and bring his extensive expertise to propel the company in its next phase of growth as a CNS clinical [...]

Ondine to acquire Advanced Photodynamic for stock

Ondine Biopharma (TSX:OBP) has agreed to acquire closely held Advanced Photodynamic Technologies of Minneapolis, Minn., a developer of photodynamic drugs and devices for anti-microbial and oncotherapeutic applications, in a share exchange. “The acquisition of Advanced Photodynamic Technologies represents an ideal strategic fit as it significantly expands our portfolio of photodynamic medical products and intellectual property,” [...]

Versant ups BioMS to “neutral”

Versant Partners upgraded BioMS Medical (TSX:MS) to “neutral” from “sell,” but stuck with its 12-month price target of 50 cents. The stock was recently quoted at 36.5 cents. Analyst Doug Loe writes that with the failure of BioMS’s Phase 3 clincial trial in secondary progressive multiple sclerosis, the company’s main asset is cash of about [...]

Amorfix game plan for 2010

Amorfix Life Sciences (TSX:AMF) has set out an ambitious list of priorities in its diagnostics and therapeutics divisions for 2010. It has four goals on the diagnostics side: • complete the National Institute for Biological Standards and Control process to validate the performance of its EP-vCJD blood screening assay using human vCJD patient samples and to [...]

Tekmira readying release of clinical data

Tekmira Pharmaceuticals (TSX: TKM) is on track to release data from its highly anticipated Phase 1 clinical trial for its lead product ApoB SNALP in the first quarter next year, CEO Dr. Mark Murray said in the third quarter report. The Vancouver-based company has leading edge technology in the area of RNA-interference and ApoB SNALP [...]

Paladin results beat consensus

RBC Capital Markets has revised upwards its financial model for Paladin Labs (TSX:PLB) after the company posted third quarter results on Wednesday that were slightly higher than consensus. Analyst Doug Miehm writes that Paladin’s results support “our positive investment thesis.  What we continue to find compelling about the story is the company’s unique strategy, with [...]

Theratechnologies presents combined Phase 3 results

Theratechnologies (TSX:TH)  presented pooled results from both its phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy at a conference in Germany. Treatments with two milligrams of tesamorelin daily for 26 weeks resulted in a significant decrease in visceral adipose tissue, no clinically significant changes in [...]

« Previous Page — Next Page »